Abstract
Background: The Covid-19 pandemic may have a deleterious impact on patients with autoimmune systemic diseases (ASD) due to their deep immune-system alterations.
Objective: This study aims to investigate the prevalence of symptomatic Covid-19 and its correlations with both organ involvement and ongoing treatments in a large series of Italian ASD patients during the first wave of pandemic.
Methods: Our multicenter telephone 6-week survey included 3,029 unselected ASD patients enrolled at 36 tertiary referral centers of northern, central, and southern Italian macro-areas with different diffusion of the pandemic. Symptomatic SARS-CoV-2 infection was classified as definite Covid-19 (presence of symptoms plus positive oral/nasopharyngeal swabs) or highly suspected Covid-19 (highly suggestive symptoms, in the absence of a swab testing).
Results: A significantly higher prevalence of definite plus highly suspected Covid-19 compared to the Italian general population was detected in the whole ASD series (p=.000), as well as in patients from the three macro-areas (p=.000 in all). Statistically higher prevalence of Covid-19 was also found in connective tissue diseases compared to chronic arthritis subgroup (p=.000) and in ASD patients with pre-existing interstitial lung involvement (p=.000). Patients treated with either conventional disease-modifying anti-rheumatic drugs (DMARDs) and/or biological DMARDs showed a significantly lower prevalence of Covid-19 (p=.000 in both). Finally, scleroderma patients undergoing low-dose aspirin showed a significantly lower rate of Covid-19 compared to those without (p=0.003).
Conclusion: The higher prevalence of Covid-19 in ASD patients, along with the significant correlations with important clinical features and therapeutic regimens, suggests the need to develop targeted prevention/management strategies during the current pandemic wave.
Keywords: Covid-19, SARS-CoV-2, autoimmune systemic diseases, rheumatic diseases, arthritis, connective tissue diseases, systemic sclerosis, interstitial lung disease.
Current Pharmaceutical Design
Title:Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments
Volume: 27 Issue: 41
Author(s): Clodoveo Ferri*, Dilia Giuggioli, Vincenzo Raimondo, Massimo L’Andolina, Lorenzo Dagna, Antonio Tavoni, Francesco Caso, Francesco Ursini, Piero Ruscitti , Maurizio Caminiti, Rosario Foti, Valeria Riccieri , Serena Guiducci, Roberta Pellegrini, Elisabetta Zanatta, Giuseppe Varcasia, Domenico Olivo, Pietro Gigliotti, Giovanna Cuomo, Giuseppe Murdaca, Riccardo Cecchetti, Rossella De Angelis, Nicoletta Romeo, Francesca Ingegnoli, Franco Cozzi, Veronica Codullo, Ilaria Cavazzana, Michele Colaci, Giuseppina Abignano, Maria De Santis, Ennio Lubrano, Enrico Fusaro, Alessandra Della Rossa, Amelia Spinella, Federica Lumetti, Giacomo De Luca, Silvia Bellando-Randone, Elisa Visalli, Ylenia Dal Bosco, Giorgio Amato, Daiana Giannini, Silvia Bilia, Francesco Masini, Greta Pellegrino, Erika Pigatto, Elena Generali, Giuseppa Pagano Mariano, Giorgio Pettiti, Giovanni Zanframundo, Raffaele Brittelli, Vincenzo Aiello, Rodolfo Caminiti, Daniela Scorpiniti, Tommaso Ferrari, Corrado Campochiaro, Veronica Brusi, Micaela Fredi, Liala Moschetti, Fabio Cacciapaglia, Laura Gragnani, Monica Monti, Serena Lorini, Sabrina Rosaria Paparo, Francesca Ragusa, Valeria Mazzi, Giusy Elia, Silvia Martina Ferrari, Ilenia Di Cola, Marta Vadacca, Sebastiano Lorusso, Simone Barsotti, Maria Letizia Aprile, Tasso Marco, Mario Miccoli , Silvia Bosello, Marco Matucci-Cerinic, Salvatore D'Angelo, Andrea Doria, Franco Franceschini, Riccardo Meliconi, Florenzo Iannone, Roberto Giacomelli, Anna Linda Zignego, Poupak Fallahi and Alessandro Antonelli*
Affiliation:
- Rheumatology Unit, University of Modena and Reggio Emilia, School of Medicine, Modena,Italy
- Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, School of Medicine, Pisa,Italy
Keywords: Covid-19, SARS-CoV-2, autoimmune systemic diseases, rheumatic diseases, arthritis, connective tissue diseases, systemic sclerosis, interstitial lung disease.
Abstract:
Background: The Covid-19 pandemic may have a deleterious impact on patients with autoimmune systemic diseases (ASD) due to their deep immune-system alterations.
Objective: This study aims to investigate the prevalence of symptomatic Covid-19 and its correlations with both organ involvement and ongoing treatments in a large series of Italian ASD patients during the first wave of pandemic.
Methods: Our multicenter telephone 6-week survey included 3,029 unselected ASD patients enrolled at 36 tertiary referral centers of northern, central, and southern Italian macro-areas with different diffusion of the pandemic. Symptomatic SARS-CoV-2 infection was classified as definite Covid-19 (presence of symptoms plus positive oral/nasopharyngeal swabs) or highly suspected Covid-19 (highly suggestive symptoms, in the absence of a swab testing).
Results: A significantly higher prevalence of definite plus highly suspected Covid-19 compared to the Italian general population was detected in the whole ASD series (p=.000), as well as in patients from the three macro-areas (p=.000 in all). Statistically higher prevalence of Covid-19 was also found in connective tissue diseases compared to chronic arthritis subgroup (p=.000) and in ASD patients with pre-existing interstitial lung involvement (p=.000). Patients treated with either conventional disease-modifying anti-rheumatic drugs (DMARDs) and/or biological DMARDs showed a significantly lower prevalence of Covid-19 (p=.000 in both). Finally, scleroderma patients undergoing low-dose aspirin showed a significantly lower rate of Covid-19 compared to those without (p=0.003).
Conclusion: The higher prevalence of Covid-19 in ASD patients, along with the significant correlations with important clinical features and therapeutic regimens, suggests the need to develop targeted prevention/management strategies during the current pandemic wave.
Export Options
About this article
Cite this article as:
Ferri Clodoveo *, Giuggioli Dilia , Raimondo Vincenzo , L’Andolina Massimo, Dagna Lorenzo , Tavoni Antonio, Caso Francesco , Ursini Francesco , Ruscitti Piero, Caminiti Maurizio , Foti Rosario , Riccieri Valeria , Guiducci Serena , Pellegrini Roberta , Zanatta Elisabetta, Varcasia Giuseppe , Olivo Domenico , Gigliotti Pietro, Cuomo Giovanna , Murdaca Giuseppe , Cecchetti Riccardo , De Angelis Rossella, Romeo Nicoletta , Ingegnoli Francesca, Cozzi Franco , Codullo Veronica , Cavazzana Ilaria , Colaci Michele, Abignano Giuseppina, De Santis Maria , Lubrano Ennio, Fusaro Enrico , Rossa Della Alessandra , Spinella Amelia , Lumetti Federica, De Luca Giacomo , Bellando-Randone Silvia , Visalli Elisa, Dal Bosco Ylenia , Amato Giorgio, Giannini Daiana , Bilia Silvia , Masini Francesco, Pellegrino Greta , Pigatto Erika, Generali Elena , Mariano Pagano Giuseppa , Pettiti Giorgio , Zanframundo Giovanni , Brittelli Raffaele, Aiello Vincenzo , Caminiti Rodolfo , Scorpiniti Daniela , Ferrari Tommaso , Campochiaro Corrado , Brusi Veronica, Fredi Micaela, Moschetti Liala , Cacciapaglia Fabio , Gragnani Laura , Monti Monica , Lorini Serena , Paparo Rosaria Sabrina, Ragusa Francesca , Mazzi Valeria , Elia Giusy, Ferrari Martina Silvia, Di Cola Ilenia , Vadacca Marta, Lorusso Sebastiano , Barsotti Simone , Aprile Letizia Maria, Marco Tasso , Miccoli Mario , Bosello Silvia , Matucci-Cerinic Marco , D'Angelo Salvatore , Doria Andrea , Franceschini Franco , Meliconi Riccardo , Iannone Florenzo, Giacomelli Roberto , Zignego Linda Anna, Fallahi Poupak and Antonelli Alessandro *, Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments, Current Pharmaceutical Design 2021; 27 (41) . https://dx.doi.org/10.2174/1381612827666210903103935
DOI https://dx.doi.org/10.2174/1381612827666210903103935 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements